Spots Global Cancer Trial Database for Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

Official Title: Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes

Study ID: NCT00167167

Conditions

Leukemia, Myeloid, Chronic

AML

MDS

Leukemia, Lymphocytic, Acute

Interventions

Donor Lymphocyte Infusion

Study Description

Brief Summary: In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.

Detailed Description: We will collect immune cells or lymphocytes from the donor's blood using a cell separator. The blood lymphocytes will be given to the subjects through a catheter. If the subjects have no complications of the first course of infusions, we may decide to give them "lymphocytes" aa second time while subjects are in remission in an attempt to prevent their disease from relapsing. A bone marrow test will be taken prior to infusion of lymphocytes as part of the clinical evaluation to receive this treatment. After lymphocyte infusions, a bone marrow will be examined about every three months for the first year to monitor progress from this therapy.